# A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

> **NCT05523167** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **argenx** · enrollment: 265 (actual)

## Conditions studied

- Active Idiopathic Inflammatory Myopathy
- Myositis
- Dermatomyositis
- Polymyositis
- Immune-Mediated Necrotizing Myopathy
- Antisynthetase Syndrome

## Interventions

- **BIOLOGICAL:** EFG PH20 SC
- **OTHER:** PBO

## Key facts

- **NCT ID:** NCT05523167
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523167, "A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05523167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*